List of works by Efstathios Kastritis

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

scientific article

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

article by Efstathios Kastritis et al published 18 April 2012 in Blood

A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.

scientific article

A review of the venous thrombotic issues associated with multiple myeloma

scientific article published on 27 May 2016

A revised international prognostic score system for Waldenström's macroglobulinemia

scientific article published on 22 May 2019

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

scientific article published on 01 January 2007

Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia

scientific article published on 01 May 2006

Abstracts

Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group

scientific article published on June 2004

Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease

scientific article

An update on the use of lenalidomide for the treatment of multiple myeloma

scientific article published on 13 July 2015

Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia

scientific article published on 01 December 2007

Angiogenesis in Waldenström's macroglobulinemia

scientific article published on March 2009

Appraising myc involvement in high risk myeloma

Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score

scientific article published on 19 March 2014

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

scientific article published on 21 November 2016

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

scientific article (publication date: 16 September 2011)

Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment

scientific article published in January 2007

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia

scientific article published on April 2010

Bortezomib for AL amyloidosis: moving forward

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

scientific article published on 19 January 2010

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

scientific article published on 4 April 2016

Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy

scientific article published in May 2006

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

scientific article

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

scientific article published on 27 February 2017

Carfilzomib for treating myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

scientific article published on 03 April 2020

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

scientific article

Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic

scientific article published on 01 June 2020

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

scientific article published on 05 October 2020

Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

scientific article published on 31 March 2018

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

scientific article published on 03 October 2020

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

scientific article published on 6 April 2012

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.

scientific article published on 30 May 2011

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

scientific article published on 24 July 2013

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

scientific article

Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece.

scientific article published in February 2010

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

scientific article published on 14 April 2020

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.

scientific article

Clinicopathological features of ovarian carcinosarcomas: a single institution experience

scientific article published in January 2005

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis

scientific article published on 25 August 2017

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment

scientific article published in January 2005

Comment on: Think to prevent before than to treat renal impairment in multiple myeloma: do not forget tubular damage mimicking Fanconi syndrome

scientific article

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

scientific article published on 20 August 2015

Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients

scientific article

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

scientific article published on 10 January 2019

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

scientific article published on 02 March 2020

Current therapy guidelines for Waldenstrom's macroglobulinaemia

scientific article published on June 2016

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia

scientific article published on 3 January 2017

Current treatments for renal failure due to multiple myeloma

scientific article published on 25 May 2013

Current treatments for renal failure due to multiple myeloma

scientific article published on 20 September 2016

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

scientific article published on March 2009

Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects

scientific article

DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA

Daratumumab combinations: what can we learn?

scientific article

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

scientific article published on 04 November 2020

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

scientific article published on 19 July 2018

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

article

Diagnosis of monoclonal gammopathy of renal significance

scientific article

Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

scientific article published on 28 May 2012

Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis

scientific article

Disease control should be the goal of therapy for WM patients

scientific article published on 28 November 2017

Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.

scientific article

Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.

scientific article published on 10 April 2013

Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma

scientific article published on 22 January 2019

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

scientific article published on 6 January 2017

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

scientific article published on 01 December 2018

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

scientific article published on 21 December 2011

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

scientific article published on 23 August 2018

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

scientific article published on 04 November 2019

Emerging antibodies for the treatment of multiple myeloma

scientific article published on 19 May 2016

Emerging drugs for Waldenström's macroglobulinemia

scientific article published on March 2011

Emerging drugs for the treatment of Waldenström macroglobulinemia

scientific article published on 21 September 2020

Emerging treatment approaches for myeloma-related bone disease

scientific article published on 17 January 2017

Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

scholarly article published in Leukemia

European Myeloma Network guidelines for the management of multiple myeloma-related complications

scientific article

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

scientific article published on 23 July 2018

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

scientific article published on 24 May 2018

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

scientific article

Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

scientific article

Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective

scientific article published on September 2012

Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients

scientific article published on 01 February 2011

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

scientific article published on 6 November 2012

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

scientific article published on 11 June 2017

Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy

scientific article published on 20 November 2015

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

scientific article published on 31 January 2018

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

scientific article

Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?

article

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

scientific article

Hematological findings and complications of COVID-19

scientific article published on 13 April 2020

Hematological malignancies: myeloma

scientific article published on September 2006

High dose melphalan in primary systemic amyloidosis: status quo?

article published in 2010

High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?

scientific article published in January 2008

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

scientific article published on 07 October 2016

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

scientific article

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

How I treat monoclonal gammopathy of renal significance (MGRS).

scientific article published on 09 October 2013

How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide

scientific article published in December 2007

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

scientific article

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents

scientific article published on 26 January 2014

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

scientific article published on 19 February 2009

Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

scientific article published on 14 December 2012

Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome

scientific article

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma

scientific article published on 8 September 2011

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

scientific article

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix

scientific article published on 21 February 2006

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel

scientific article published on 15 February 2017

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications

scientific article published on 23 January 2020

Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

scientific article published in January 2006

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

scientific article

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

scientific article published on 20 February 2010

Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.

scientific article published on 17 February 2014

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

scientific article published on 04 August 2011

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

scientific article published on 07 May 2020

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

scientific article published on 9 March 2015

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

scientific article published on 07 November 2018

Management of relapsed and relapsed refractory myeloma

scientific article published on December 2007

Managing renal complications in multiple myeloma

scientific article

Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract

scientific article

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

scientific article published on 13 September 2012

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma

scientific article

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

scientific article published in July 2012

Multiple myeloma: Role of autologous transplantation

scientific article published on 11 November 2019

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

scientific article published on 20 December 2008

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

scientific article published on 3 November 2015

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

scientific article published on 22 October 2012

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

scientific article published on 12 August 2020

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

scientific article published on 20 April 2011

Novel approaches for reducing free light chains in patients with myeloma kidney.

scientific article published on 21 February 2012

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

scientific article published in December 2005

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

scientific article

Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

scientific article published on June 2005

Pathogenesis and treatment of renal failure in multiple myeloma

scientific article

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection

scientific article published on 25 December 2020

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

scientific article

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

scientific article

Prevention and treatment of myeloma bone disease

scientific article published on December 2012

Primary Systemic Amyloidosis (AL)

Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics

scientific article published in March 1996

Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance

scientific article published on 4 January 2016

Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis

scientific article published on 13 May 2020

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

scientific article published on 4 September 2013

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

scientific article published on 01 October 2019

Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group

scientific article published in January 2002

Prognosis and risk assessment in AL amyloidosis - There and back again

scientific article published in May 2017

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

scientific article

Prognostication of the High-Risk WM Patient

scientific article published on 01 February 2011

Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial

scientific article published on November 2010

Proteasome inhibitor associated thrombotic microangiopathy

scientific article

Proteasome inhibitor therapy for Waldenström's macroglobulinemia

scientific article published on 02 April 2013

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

scientific article published on 01 February 2019

Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments

scientific article published in January 2007

Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma

scientific article published on 9 September 2016

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group

scientific article published on 12 February 2020

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

scientific article published on 9 March 2018

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 01 April 2020

Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma

scientific article

Recent advances in the management of AL Amyloidosis

scientific article

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

scientific article published on 05 July 2016

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

scientific article published on 9 August 2008

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

scientific article

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

scientific article published on 28 March 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

scientific article published on 27 July 2020

Reply to S. Girnius et al.

scientific article published in July 2013

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

scientific article

Response to bortezomib of a patient with scleromyxedema refractory to other therapies

article

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

scientific article published on 01 April 2007

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

scientific article published on 26 May 2010

Rituximab-based treatments in Waldenström's macroglobulinemia

scientific article published on March 2009

Schnitzler's syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment.

scientific article published on December 2008

Sclerostin: a possible target for the management of cancer-induced bone disease

scientific article published on 05 July 2012

Screening for Gaucher disease among patients with plasma cell dyscrasias

scientific article published on 30 September 2019

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

scientific article

Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report

scientific article published on 21 September 2020

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

scientific article published on May 2009

Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity

article

Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.

scientific article published on 19 September 2016

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

scientific article

Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?

scientific article published on 01 December 2020

Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication

scientific article

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

scientific article published on 11 July 2020

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma

scientific article published on 13 November 2015

Targeted therapies in multiple myeloma

scientific article published on 17 January 2009

Thalidomide in the treatment of multiple myeloma

scientific article published in December 2007

Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma

scientific article

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

scientific article published on 26 February 2016

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP

scientific article

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

scientific article

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function

article by Athanasios Dimopoulos et al published 7 June 2011 in Annals of Oncology

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

scientific article published on 25 September 2020

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

scientific article published on 22 November 2017

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

scientific article

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

scientific article

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

scholarly article by Evangelos Terpos et al published 15 October 2013 in American Journal of Hematology

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

scientific article published on 01 January 2019

The evolving role of lenalidomide in the treatment of hematologic malignancies

scientific article published on March 2007

The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy

scientific article published on 09 October 2006

The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy

scientific article published on 26 July 2005

The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy

scientific article published in February 2005

The patient with myeloma

The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma

scientific article published on 31 July 2014

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

The role of novel drugs in multiple myeloma

scientific article published on September 2008

Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

article

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

scientific article published on 27 July 2020

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop

scientific article published on 01 March 2019

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

scientific article

Treatment of light chain deposition disease with bortezomib and dexamethasone

scientific article

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

scientific article published on May 2008

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

scientific article published on 26 August 2010

Treatment of plasma cell dyscrasias with lenalidomide

scientific article published on 29 May 2008

Treatment of relapsed/refractory multiple myeloma

scientific article published on April 2009

Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors

scientific article published in November 2004

Treatment options for relapsed and refractory multiple myeloma

scientific article published on 02 April 2015

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

scientific article

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

scientific article published on 18 July 2016

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

scientific article published on December 2008

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

scientific article

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

scientific article

VWF, WM, and angiogenesis: is there a link?

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

scientific article

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

scientific article

Waldenström’s Macroglobulinemia

Waldenström’s Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects

When a little aspirin may be enough

Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience

scientific article published on 4 August 2006

Paulina is supported by:

About Paulina

Help